levacetylleucine 1000 MG Granules for Oral Suspension [Aqneursa]
- RxCUI
- 2693623
- RxNorm name
- levacetylleucine 1000 MG Granules for Oral Suspension [Aqneursa]
- Display name
- levacetylleucine 1000 MG Granules for Oral Suspension [Aqneursa]
- Full name
- levacetylleucine 1000 MG Granules for Oral Suspension [Aqneursa]
- Term type
- SBD
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:38:47
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| AQNEURSA | LEVACETYLLEUCINE | IntraBio Inc | 0f248e55-d1bb-13f9-e063-6294a90a05ce | 2026-09-17 | Warnings, Adverse reactions | 2693623 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
DailyMed RxNorm Mappings#
| Set ID | RxNorm mappings | Terms | SPL version | Label | Effective |
|---|---|---|---|---|---|
| 0f248e55-d1bb-13f9-e063-6294a90a05ce | AQNEURSA 1 GM Granules for Oral Suspension [PSN] · levacetylleucine 1000 MG Granules for Oral Suspension [Aqneursa] [SBD] · Aqneursa 1 GM Granules for Oral Suspension [SY] · Aqneursa 1000 MG Granules for Oral Suspension [SY] | 4 | 5 | These highlights do not include all the information needed to use AQNEURSA safely and effectively. See full prescribing information for AQNEURSA. AQNEURSA™ (levacetylleucine) for oral suspension Initial U.S. Approval: 2024 | 20250123 |